Lauren M. Slosky About Dr. Lauren M. Lauren M.

“We’re enhancing the powerful pain-relieving effects of opioids while limiting respiratory depression He is particularly excited by the novel application of PAMs in chronic and neuropathic pain models , Discovering breakthrough results in neuroma pain models via a spontaneous collaboration. Ben M Clements is a behavioral pharmacologist who uses in vitro and in vivo models to discover and characterize novel treatments for chronic pain and opioid use disorder.

The connection runs deeper than science: Zhao's grandmother worked as a pharmacologist on diabetes in China University 06:49 First contact with G proteins - the muscarinic receptor as a tool, not a subject 09:17 From China

Kathleen Caron About Kathleen M. Caron Kathleen M. Caron, Ph.D. is the Frederik L. Kathleen M. Caron on the web Lab Website Twitter Pubmed Google Scholar Orcid Unlock the Full Dr.

mechanisms of flavonoids in cancer using nuclear magnetic resonance spectroscopy (NMR) led to a Barry M.

Alex Serafini Strategy: From Personal Pain to Scientific Purpose Dr. pain research at Hopkins and later an MD-PhD at Mount Sinai. His early exposure to TRPV1 channels and peripheral pain mechanisms with Dr. Pain became more than biology — it became a personal strategy. “Half the time, in pain, what works in vivo doesn’t translate to clinic.

Founder & Director Yamina Berchiche Get in touch Co-Founder Attila Foris Get in touch Board Member Anne M.

Pradhan returns to often: that organisms in chronic pain are fundamentally different biological systems been her scientific focus for nearly two decades, through failed clinical trials in depression and pain Chicago, where her lab studies opioid receptor biology in the context of headache disorders, chronic pain Delta opioid agonists appear to relieve the same symptoms — pain, negative affect, and aura-related signs After failed trials in depression and pain, Dr.

Biotech founder Ajay Yekkirala shares how AI, GPCRs, and bold questions are driving next-gen pain therapeutics breakthrough GPCR research career The inside story behind founding Blue Therapeutics and targeting supraspinal pain Woolf at Boston Children’s Hospital and Harvard Medical School, where he deepened his understanding of pain Driven by the opioid crisis and the lack of non-addictive pain treatments, Ajay co-founded Blue Therapeutics , a biotech startup focused on targeting supraspinal GPCRs for chronic pain.

recurring example: the same molecule promotes opioid antinociception in one context, drives chronic pain the dorsal horn lights up with phospho-ERK in response to opioid, routing through RSK1/2 to stronger pain With a non-selective HSP90 inhibitor given systemically, the brain effect dominates and pain relief is a six-hour feeding window for seven days increased morphine's antinociceptive efficacy in multiple pain But second-generation pan-HSP90 inhibitors have shown acceptable tolerability in oncology trials, Dr.

I spent time running for the chair of International Affairs for the U-M Postdoctoral Association (UMPDA

Nigel Bunnett at the NYU Pain Research Center as a postdoctoral researcher. focuses on investigating GPCR signaling and trafficking in the context of inflammation and chronic pain Next Steps Badr will continue focusing his research on GPCRs involved in pain and inflammation during Badr shared his passion for GPCR signalling and regulation, specifically in the context of pain and inflammation

Journey Today Meet the Leadership Founder & Director Yamina Berchiche Get in Touch Board Member Anne M.

Kathleen Caron " "Kathleen M. Caron, Ph.D. is the Frederik L.

conjugates to target GPCRs, with a focus on receptors relevant for treating osteoporosis, diabetes, and pain

neurons), Vollum Institute Portland (visiting scientist with Ed McCleskey, sensory neuron properties); Pain

passion, I recently started a postdoctoral fellowship to study the role of GPCRs in the mechanisms of pain

The therapeutic logic is that decoupling from the orthosteric site might preserve pain relief while altering We enhance your endogenous tone, we cause pain relief, maybe we mitigate some of these side effects."

If the right ligand could engage G-protein signaling while sparing β-arrestin, pain relief might finally characterization of the pharmacological properties of cannabinoids in conjunction with terpenes for pain

Klein's lab where she helped to investigate the role of various ATP-sensitive potassium channels in pain

But loss has a way of sharpening focus—friends lost to overdose brought the opioid epidemic into painful

conjugates to target GPCRs, with a focus on receptors relevant for treating osteoporosis, diabetes, and pain

The guests frame their work as talking to peers who understand the same pains, not selling a catalog.

of opioid receptors and is currently focusing on the pharmacology of cannabinoids in the context of pain

encompassing neurological and psychiatric disorders, cardiovascular disease, obesity, diabetes, chronic pain

Classified GPCR News Let’s dive into the Classified GPCR News from February 10th to 16th, 2025 Industry News Pain administration in spinal cord injury GPR37L1 identifies spinal cord astrocytes and protects neuropathic pain Neuroregeneration , EPSC , GLT-1 , GPR37L1 , SPM , astrocytes , maresin 1 , microglia , nerve injury , neuropathic pain

encompassing neurological and psychiatric disorders, cardiovascular disease, obesity, diabetes, chronic pain

encompassing neurological and psychiatric disorders, cardiovascular disease, obesity, diabetes, chronic pain

biology into traditionally pharmacology-driven GPCR programs and worked across migraine, cardiovascular, pain

The scientists who persist, in her framing, are not the ones who feel less pain from those setbacks,